monocyt
macrophag
play
import
role
pathogenesi
inflammatori
diseas
multipl
sclerosi
ms
rheumatoid
arthriti
ra
ms
macrophag
differenti
activ
demonstr
induc
demyelin
ra
number
macrophag
infiltr
synovi
tissu
correl
extent
local
diseas
activ
activ
macrophag
import
sourc
matrix
metalloproteinas
mmp
macrophag
primari
effector
tissu
destruct
particip
degrad
normal
abnorm
matrix
inflammatori
diseas
like
ms
ra
therapeut
strategi
aim
counteract
macrophag
home
activ
differenti
furthermor
macrophag
key
player
develop
progress
atherosclerosi
meanwhil
acknowledg
chronic
inflammatori
diseas
also
known
extracellular
matrix
metalloproteinas
induc
emmprin
cell
surfac
glycoprotein
express
activ
monocyt
macrophag
demonstr
stimul
product
sever
mmp
includ
mmp
contribut
pathogenesi
ms
particip
remodel
extracellular
matrix
chronic
inflammatori
process
predomin
acut
ms
lesion
also
particip
gener
autoimmun
ms
cleav
myelin
compound
imbal
mmp
activ
also
implic
ra
contribut
joint
destruct
directli
degrad
cartilag
bone
promot
angiogenesi
sever
mmp
includ
contribut
atherosclerosi
initi
collagen
breakdown
plaqu
undergo
extens
posttransl
process
exhibit
remark
variat
size
rang
approxim
kda
glycan
content
kda
highli
glycosyl
high
molecular
weight
form
induc
mmp
product
wherea
lowli
glycosyl
low
molecular
weight
form
shown
inhibit
mmp
function
statin
inhibitor
coenzym
hmgcoa
reductas
catalyz
rate
limit
step
cholesterol
biosynthesi
pathway
apart
cholesterol
lower
activ
statin
demonstr
immunomodulatori
effect
vitro
anim
model
prove
effect
control
trial
statin
may
serv
treatment
option
ms
ra
futur
atherosclerosi
prevent
statin
alreadi
wide
use
statin
block
format
cholesterol
biosynthesi
pathway
intermedi
isoprenoid
dolichol
fig
isoprenoid
deriv
farnesylpyrophosph
fpp
geranylgeranylpyrophosph
ggpp
form
lipid
attach
import
membran
transloc
small
gtp
bind
protein
upon
isoprenyl
gtp
bind
protein
abl
signal
downstream
effector
promot
vital
cellular
function
convers
isoprenyl
inhibit
statin
inact
form
gtp
bind
protein
accumul
cytosol
keep
cell
dormant
state
furthermor
reduct
fpp
statin
result
deplet
dolichol
act
carbohydr
donor
nlink
glycosyl
membran
target
protein
lower
level
nglycosyl
result
accumul
immatur
form
protein
endoplasm
reticulum
studi
investig
role
statin
inhibit
monocyt
differenti
associ
process
mmp
secret
modul
fluvastatin
novarti
germani
atorvastatin
pfizer
karlsruh
germani
dissolv
dimethylsulfoxid
dmso
use
vehicl
control
sigma
st
loui
mo
use
concentr
rang
pravastatin
merck
darmstadt
germani
dissolv
water
use
concentr
mevalon
squalen
watersolubl
cholesterol
sigma
use
final
concentr
farnesylpyrophosph
fpp
geranylgeranylpyrophosph
ggpp
sigma
dolichol
larodan
sweden
use
follow
inhibitor
cholesterol
biosynthesi
pathway
use
farnesyl
transferas
inhibitor
fti
geranylgeranyl
transferas
inhibitor
ggti
farnesylgeranylgeranyl
transferas
inhibitor
merck
tunicamycin
sigma
potent
inhibitor
nglycosyl
newli
form
protein
use
concentr
peptid
antagonist
biologischmedizinisch
forschungszentrum
germani
puriti
assess
high
pressur
liquid
chromatographi
antihuman
fitclabel
monoclon
antibodi
clone
mem
mous
immunotool
friesoyth
germani
allophycyanin
apc
label
monoclon
antibodi
becton
dickinson
san
jose
ca
use
flow
cytometri
monoclon
antibodi
mem
immunotool
also
use
immunoblot
experi
perform
human
monocyt
cell
line
kind
gift
dr
angelika
bierhau
univers
heidelberg
germani
cell
cultur
rpmi
medium
supplement
fc
gibco
brl
gaithersburg
md
penicillinstreptomycin
lglutamin
gibco
humidifi
atmospher
induct
differenti
cell
x
seed
presenc
nm
acet
pma
merck
incub
h
incub
nonattach
cell
remov
aspir
adher
cell
wash
three
time
medium
undifferenti
cell
seed
incub
without
pma
use
control
express
pattern
determin
flow
cytometri
cell
per
well
wash
pb
paa
laboratori
pasch
austria
stain
buffer
contain
fc
incub
respect
antibodi
min
wash
three
time
stain
buffer
cell
analyz
instrument
becton
dickinson
use
softwar
treestar
ashland
cell
incub
statin
control
differenti
pma
upregul
cell
simultan
permeabil
fix
cell
permeabil
buffer
contain
paraformaldehyd
bd
becton
dickinson
flow
cytometri
use
monitor
intracellular
express
cell
preincub
statin
control
differenti
pma
h
cell
lyse
ml
ripa
buffer
supplement
sodium
orthovand
sigma
complet
proteas
inhibitor
cocktail
roch
indianapoli
min
intermitt
shake
ice
protein
separ
sdspage
gel
transfer
pvdf
membran
use
transblot
instrument
biorad
hercul
ca
v
h
immunoblot
block
h
lipid
free
milk
incub
antibodi
immunotool
h
follow
min
wash
primari
antibodi
conjug
goat
antimous
secondari
antibodyhorseradish
peroxidas
hrp
becton
dickinson
incub
h
final
blot
develop
use
ecl
develop
system
amersham
buckinghamshir
uk
enhanc
ecl
system
pierc
rockford
il
imag
analyz
use
imagej
softwar
nih
bethesda
md
cellular
mmp
product
measur
cell
supernat
assess
mmp
secret
supernat
collect
incub
statin
control
mmp
activ
determin
sdspolyacrylamid
gel
zymographi
sampl
centrifug
remov
cellular
debri
supernat
collect
store
ten
supernat
mix
sd
load
buffer
invitrogen
carlsbad
ca
load
onto
polyacrylamid
gel
contain
gelatin
sigma
posit
control
r
system
minneapoli
mn
ad
gel
electrophoresi
v
min
gel
renatur
renatur
buffer
invitrogen
contain
triton
min
equilibr
develop
buffer
invitrogen
min
fresh
develop
buffer
ad
gelatin
contain
gel
allow
develop
overnight
gelatin
gel
stain
coomassi
blue
sigma
destain
buffer
consist
acet
acid
methanol
distil
water
min
visual
zymogen
band
produc
mmp
digest
imag
gel
scan
dri
imag
analyz
use
imagej
softwar
nih
assess
proport
molecul
reach
cell
surfac
cell
x
cell
seed
ml
dish
differenti
pma
treat
tunicamycin
indic
statin
cell
wash
three
time
cold
pb
slowli
agit
mgml
biotin
sulfonhsbiotin
pierc
min
ice
cell
lyse
use
lysi
buffer
contain
sd
phenylmethylsulfonyl
fluorid
benzamidin
streptavidin
agaros
bead
wash
lysi
buffer
mix
cell
lysat
thoroughli
mix
cell
lysat
biotinyl
protein
pull
bead
elut
sd
laemmli
buffer
immunoblot
describ
applic
student
ttest
perform
statist
analysi
pvalu
accept
signific
cultur
cell
round
nonadher
fig
differenti
cell
pma
result
chang
morpholog
cell
becom
flat
elong
amoeboid
adher
fig
contrast
treatment
variou
statin
pravastatin
atorvastatin
fluvastatin
follow
differenti
pma
result
cellular
morpholog
similar
undifferenti
cell
pravastatin
treatment
also
result
format
bunch
cluster
cell
fig
next
rescu
experi
perform
revers
effect
statin
treatment
mevalon
product
hmgcoa
reductas
revers
effect
fluvastatin
result
differenti
cellular
morpholog
fig
addit
downstream
intermedi
fpp
ggpp
dolichol
also
revers
effect
fluvastatin
although
decreas
degre
dolichol
exhibit
weakest
effect
induc
differenti
cellular
morpholog
fig
tunicamycin
inhibitor
nglycosyl
prevent
differenti
cell
similar
manner
statin
fig
inhibit
isoprenyl
partial
abl
prevent
differenti
cell
fig
flow
cytometr
analysi
reveal
surfac
express
upregul
pmadifferenti
cell
fig
treatment
cell
pravastatin
atorvastatin
fluvastatin
result
downregul
fig
rescu
experi
reveal
treatment
dolichol
fig
fpp
fig
rescu
express
wherea
ggpp
treatment
partial
rescu
express
fig
inhibitor
experi
tunicamycin
treatment
induc
potent
inhibit
express
follow
fig
indic
farnesyl
may
domin
pathway
regul
express
express
monocyt
differenti
antigen
regul
manner
similar
therefor
monitor
express
along
pmamedi
differenti
accompani
increas
express
fig
inhibit
treatment
three
statin
fig
rescu
experi
confirm
dolichol
fig
fpp
fig
almost
complet
rescu
differenti
cell
wherea
ggpp
fail
fig
inhibit
experi
inhibitor
test
similar
effect
express
fig
assess
downregul
cell
surfac
express
caus
decreas
overal
protein
level
membran
transloc
next
measur
express
permeabil
cell
repres
total
cellular
level
compar
cell
surfac
express
nonpermeabil
cell
result
demonstr
pmadifferenti
cell
molecul
express
cell
surfac
fig
fluvastatin
induc
intracellular
retent
fig
revers
upon
fpp
treatment
fig
effect
fluvastatin
mimick
tunicamycin
treatment
fig
exist
two
differ
glycosyl
form
highli
glycosyl
higher
molecular
weight
hg
form
lowli
glycosyl
lower
molecular
weight
lg
form
hg
form
homooligom
induc
mmp
secret
activ
wherea
lg
inhibit
mmp
secret
experiment
induc
chang
nglycosyl
illustr
fig
treatment
cell
fluvastatin
induc
lg
express
dosedepend
manner
rescu
mevalon
squalen
cholesterol
abl
reduc
fluvastatininduc
increas
express
lg
inhibit
isoprenyl
combin
inhibitor
farnesyl
geranylgeranyl
increas
lg
consist
treatment
specif
peptid
antagonist
increas
lg
treatment
cell
tunicamycin
affect
level
lg
hg
express
lg
kda
hg
kda
greatli
diminish
molecular
weight
form
appear
upon
tunicamycin
treatment
kda
consist
nonglycosyl
core
protein
small
amount
kda
hg
remain
like
synthes
tunicamycin
treatment
fig
confirm
result
flow
cytometri
experi
compar
permeabil
nonpermeabil
cell
quantifi
intracellular
retent
surfac
biotinyl
perform
measur
express
cell
surfac
cell
surfac
level
markedli
downregul
treatment
three
statin
control
substanc
tunicamycin
decreas
transloc
cell
surfac
fig
greater
degre
statin
consist
biotinyl
cell
surfac
form
core
protein
could
detect
western
blot
detect
cell
lysat
fig
exist
sever
form
proform
kda
activ
form
kda
heterodim
kda
homodim
kda
gelatin
zymographi
abl
measur
activ
form
pmainduc
differenti
cell
promot
activ
indic
emerg
activ
form
treatment
fluvastatin
result
decreas
level
activ
wherea
pravastatin
atorvastatin
fail
rescu
effect
fluvastatin
ad
mevalon
fpp
ggpp
dolichol
mevalon
dolichol
abl
increas
level
activ
wherea
fpp
ggpp
inhibit
experi
reveal
tunicamycin
inhibit
express
activ
fig
exist
two
form
proform
kda
activ
form
kda
pma
differenti
upregul
level
activ
cell
fluvastatin
reduc
activ
level
wherea
pravastatin
atorvastatin
dolichol
mevalon
treatment
rescu
activ
tunicamycin
treatment
mimick
effect
fluvastatin
fig
inflamm
infect
monocyt
migrat
peripher
compart
target
organ
matur
differenti
tissu
macrophag
matur
process
result
releas
sever
inflammatori
cytokin
factor
mmp
one
major
factor
report
influenc
monocyt
differenti
process
pivot
role
monocyt
differenti
confirm
fact
specif
peptid
antagonist
prevent
monocyt
differenti
furthermor
demonstr
significantli
inhibit
secret
activ
cell
thu
emphas
role
regul
mmp
interact
adhes
marker
larg
neutral
amino
acid
transport
particip
integrinmedi
adhes
cellular
differenti
apoptosi
inhibit
also
shown
impair
transloc
monocarboxyl
transport
mct
cell
surfac
disrupt
cellular
lactat
acid
shuttl
lead
intracellular
acidif
metabol
starvat
effect
lead
inhibit
monocyt
differenti
statin
hmgcoa
reductas
inhibitor
shown
promot
benefici
effect
autoimmun
condit
although
origin
function
statin
lower
plasma
low
densiti
lipoprotein
cholesterol
cholesterol
independ
effect
also
demonstr
monocyt
statin
shown
inhibit
proinflammatori
respons
abort
function
differenti
monocyt
inhibit
mmp
secret
activ
howev
mechan
regul
process
yet
complet
elucid
hypothes
inhibit
monocyt
differenti
statin
mediat
major
player
monocyt
differenti
process
studi
statin
inhibit
differenti
cell
evidenc
decreas
adher
statin
treatment
also
alter
morpholog
cell
thu
indic
statin
interfer
cellular
differenti
known
effect
statin
farnesyl
dolichol
hypothes
statin
influenc
molecular
structur
extracellular
domain
three
put
nlink
glycosyl
site
could
potenti
inhibit
statin
treatment
exist
two
differ
glycosyl
state
hg
highli
glycosyl
lg
lowli
glycosyl
form
mmp
induct
promot
hg
via
homooligomer
wherea
lg
act
inhibitor
probabl
affin
caveolin
thu
glycosyl
statu
act
molecular
switch
activ
mmp
result
show
fluvastatin
treatment
increas
express
lg
confirm
role
mediat
statinassoci
mmp
inhibit
cell
permeabil
studi
statintr
cell
reveal
statininduc
inhibit
express
pronounc
cell
surfac
compar
intracellular
compart
therefor
hypothes
statin
regul
express
posttransl
mechan
eg
isoprenyl
nglycosyl
intracellular
retent
immatur
proform
rather
chang
genom
level
observ
surmis
isoprenyl
nglycosyl
contribut
express
activ
mevalonatedepend
pathway
inhibit
treatment
statin
one
possibl
mechan
statininduc
effect
nlink
glycosyl
dolichol
act
carbohydr
donor
nglycosyl
membran
target
protein
dolichol
product
regul
fpp
downstream
mevalon
two
distinct
inhibitor
isoprenyl
farnesyl
inhibitor
geranylgeranyl
inhibitor
partial
inhibit
surfac
express
mmp
activ
indic
isoprenyl
play
minor
role
pathway
howev
isoprenyl
inhibitor
induc
express
lg
form
specul
discrep
due
potenti
effect
statin
mediat
isoprenyl
upregul
also
promot
lg
form
subsequ
decreas
selfassoci
cell
surfac
thu
statin
act
isoprenyl
pathway
impair
traffick
cell
surfac
tunicamycin
specif
inhibit
nglycosyl
newli
synthes
protein
experi
tunicamycin
drastic
reduc
de
novo
nglycosyl
result
greatli
increas
express
nonglycosyl
core
protein
taken
togeth
data
suggest
statin
regul
multipl
level
particularli
isoprenyl
nglycosyl
transmembran
protein
sensit
chang
glycosyl
statu
requir
high
level
glycosyl
mmp
stimul
activ
unusu
uniqu
like
insulinlik
growth
factor
igf
receptor
membranetarget
molecul
requir
nglycosyl
proper
function
reduc
glycosyl
activ
caus
proreceptor
retent
within
endoplasm
reticulum
consist
find
two
group
describ
downregul
receptor
statin
treatment
demonstr
inhibitori
effect
via
isoprenyl
nglycosyl
pathway
act
synergist
promot
receptor
activ
taken
togeth
previou
report
shown
statin
analysi
statin
effect
key
player
surround
cyclophilin
increas
understand
mechan
underli
effect
potent
pleiotrop
agent
postul
statin
produc
antiinflammatori
effect
monocyt
macrophag
influenc
make
interest
candid
therapeut
strategi
autoimmun
disord
ms
ra
howev
formal
proof
clinic
efficaci
still
pend
contrast
statin
alreadi
wide
use
primari
prevent
atherosclerosi
properti
statin
effect
cancer
merit
research
